June 19, 2013
Takeda Pharmaceutical said on June 18 that its dipeptidyl peptidase-4 (DPP-4) inhibitor Nesina (alogliptin) and two fixed-dose combination drugs containing the compound are now available in the US market. The company’s local arm, Takeda Pharmaceuticals U.S.A. Inc., will independently market...read more